Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
- Do you still think Pfizer COVID-19 vaccine effective?
- How is the first batch of frozen people after 50 years?
- COVID-19 infection increases risk of a range of neurological diseases,
- Cancer patients eating ice cream can reduce this side effect of chemotherapy
- Gut microbes may become a new therapy for depression and anxiety
- The risk of Alzheimer’s disease increases by 50-80% within a year after COVID-19 infection
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall.
Moderna hopes to launch a vaccine against Covid-19, influenza and respiratory syncytial virus (a common respiratory virus) as early as fall 2023, Chief Executive Stephane Bancel said on Monday. The three-in-one vaccine booster shot.
Moderna’s chief executive, Stéphane Bancel, said the company’s goal is to have the compound vaccine available in multiple countries in the next 18 months or so.
In addition to immunizing people against Covid-19 and the flu virus, the vaccine will target respiratory syncytial virus (RSV), a common virus that often causes cold-like symptoms.
“Our goal is to develop a booster shot with only one dose per year. If people don’t want to get 2 or 3 doses of vaccine every winter, they just want to get one dose, so there will be no compliance issues.” Bancel in the world Speaking at a virtual roundtable of the World Economic Forum.
In the best-case scenario, the compound vaccine would be available in some countries by the fall of 2023, Bancel said.
He said that the RSV project is in the third phase of trials, which is the final stage of human testing; while the influenza project is in the second phase of trials and is expected to enter the third phase of trials in the second quarter of this year.
Bancel also said that Moderna’s vaccine candidate for the mutated virus Omicron has basically been developed and is about to enter the clinical stage.
The company expects to share data with regulators around March, he added.
Like Pfizer and its partner BioNTech, Moderna has developed a Covid-19 vaccine using advanced messenger RNA (mRNA) technology that differs from traditional vaccines, and has achieved impressive results. The company and its shareholders hope to see more growth from mRNA technology in the future.
Moderna: (COVIDD-19 Influenza RSV) three-in-one vaccine is expected to be available next fall
(source:internet, reference only)
Disclaimer of medicaltrend.org
